Benzinga | Mar 17, 2021 06:52AM EDT

HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Lowers Price Target to $61

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and lowers the price target from $64 to $61.